willow glp 1 tablet reviews GLP-1 Microbiome+ (3-Month Supply) NAD Reccomends Willow Health Discontinue

Ahadiat S-A, Hosseinian Z

Case 1 Male patient died while receiving semaglutide report invalidated because call-center contractors claimed patient identifier was missing (FDA found it in source documents) Case 2 Consumer taking liraglutide suffered a disabling stroke report cancelled because the consumer said it was unrelated to the drug Case 3 Patient taking semaglutide became depressed and committed suicide no follow-up attempts documented, still not submitted to FDA as of March 2026 Case 4 Consumer reported suicidal ideation on semaglutide in December 2024 not reviewed until February 2025, only after FDA inspectors flagged it Case 5 FDA found Novo Nordisk's written procedures allowed adverse events to be rejected based on causality assessments contradicting federal reporting requirements A Second Front: Vision Loss Claims Beyond the GI injury cases, a second GLP-1 MDL was created in December 2025 for vision loss claims

$1,300+ retail Zepbound: $349 cash-pay (via manufacturer program)

Patients who used Zepbound for 36 weeks lost an average of 21%, but then, when switched to a placebo, after 1 year, they had regained 14% of their weight back

A total of 992 patients were identified as using an SGLT2i without ever having been prescribed a GLP-1 RA